Porphyrin-containing Gadolinium Complex as a Tumor-targeting Magnetic Resonance Imaging (MRI) Contrast Agent

Area of Science:

• * Chemical Synthesis and Characterization
• * In Vitro and In Vivo Evaluation of MRI Contrast Agents

Background:

• * Development of targeted contrast agents for improved Magnetic Resonance Imaging (MRI).
• * Limitations of conventional gadolinium-based contrast agents (GBCAs) in tumor specificity.

Purpose of the Study:

• * Synthesize and characterize a novel gadolinium complex, Gd-DTPA-2APTSPP.
• * Evaluate the in vitro and in vivo properties of Gd-DTPA-2APTSPP as a potential tumor-targeting MRI contrast agent.

Main Methods:

• * Synthesis of Gd-DTPA-2APTSPP via reaction of diethylenetriaminepentaacetic dianhydride with 5-(4'-aminophenyl)-10,15,20-tris(4'-sulfonatophenyl) porphyrin, followed by gadolinium chelation.
• * In vitro characterization including cytotoxicity assays on HeLa cells.
• * In vivo evaluation using VX2 carcinoma model in rabbits to assess signal enhancement and tumor specificity.

Main Results:

• * Gd-DTPA-2APTSPP exhibited high relaxivity (r1) and low cytotoxicity to HeLa cells.
• * Demonstrated significantly enhanced and prolonged signal intensities in VX2 carcinoma in rabbits compared to Gd-DTPA.
• * Successfully distinguished VX2 carcinoma from reactive hyperplasia and normal tissues.

Conclusions:

• * Gd-DTPA-2APTSPP shows selective uptake by tumors.
• * The novel agent holds significant potential as a tumor-targeting MRI contrast agent.
• * Further research is warranted to explore its clinical applicability.